Lonza Group AG

Lonza Group AG is a leading global contract development and manufacturing organization (CDMO) serving the healthcare sector. Established in 1897 and headquartered in Basel, Switzerland, the company is recognized for transforming scientific breakthroughs from biotechs and pharmaceutical firms into viable, life-saving therapies. Lonza’s service offerings span integrated biologics, advanced synthesis, and specialized modalities, covering the full lifecycle from early drug development to commercial manufacturing. The company’s expertise includes mammalian and microbial biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, and cutting-edge cell and gene therapies. Employing approximately 18,000 people across more than 30 sites worldwide, Lonza operates a vast network to address the complex needs of its global clientele. In recent years, the company has focused on streamlining its portfolio to concentrate on core CDMO services, reinforcing its position as an industry leader in biopharmaceutical manufacturing and innovation for the pharmaceutical, biotechnology, and life sciences markets.